Molecular Subtyping in Breast Cancer
Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast can
Clinical Pearls
Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast cancer.
- ASCO and CAP are trying to better define patients who may benefit from treatment with targeted therapies
- The current method of detecting HER2 overexpression/amplification may miss a portion of patients; molecular subtyping is a more accurate way to identify these patients
- A different molecular profiling signature should be offered to patients who are defined by current guidelines as 'borderline'
<<<
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
